617 related articles for article (PubMed ID: 16885180)
21. Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes.
Nguyen D; Emond MJ; Mayer-Hamblett N; Saiman L; Marshall BC; Burns JL
Pediatr Pulmonol; 2007 Jun; 42(6):533-41. PubMed ID: 17469154
[TBL] [Abstract][Full Text] [Related]
22. [Use of inhaled tobramycin in patients with cystic fibrosis].
Chermenskiĭ AG; Gembitskaia TE
Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.
Maciá MD; Borrell N; Segura M; Gómez C; Pérez JL; Oliver A
Antimicrob Agents Chemother; 2006 Mar; 50(3):975-83. PubMed ID: 16495260
[TBL] [Abstract][Full Text] [Related]
24. Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland.
Stelmach I; Korzeniewska A; Stelmach W
Respiration; 2008; 75(2):178-81. PubMed ID: 17435382
[TBL] [Abstract][Full Text] [Related]
25. Suboptimal aminoglycoside dosing in critically ill patients.
Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
[TBL] [Abstract][Full Text] [Related]
26. Determination of tobramycin in saliva is not suitable for therapeutic drug monitoring of patients with cystic fibrosis.
Madsen V; Lind A; Rasmussen M; Coulthard K
J Cyst Fibros; 2004 Dec; 3(4):249-51. PubMed ID: 15698943
[TBL] [Abstract][Full Text] [Related]
27. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
Stass H; Dalhoff A
Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
[TBL] [Abstract][Full Text] [Related]
28. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
[TBL] [Abstract][Full Text] [Related]
29. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
Strateva T; Petrova G; Mitov I
J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
[TBL] [Abstract][Full Text] [Related]
30. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
[TBL] [Abstract][Full Text] [Related]
31. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.
Elborn JS; Henig NR
Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707
[TBL] [Abstract][Full Text] [Related]
32. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
McCaughey G; McKevitt M; Elborn JS; Tunney MM
J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
[TBL] [Abstract][Full Text] [Related]
33. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
[TBL] [Abstract][Full Text] [Related]
34. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial.
Kabra SK; Pawaiya R; Lodha R; Kapil A; Kabra M; Vani AS; Agarwal G; Shastri SS
J Cyst Fibros; 2010 Jan; 9(1):17-23. PubMed ID: 19818694
[TBL] [Abstract][Full Text] [Related]
35. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
[TBL] [Abstract][Full Text] [Related]
36. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic/pharmacodynamic analysis of weight- and height-scaled tobramycin dosage regimens for patients with cystic fibrosis.
Alghanem SS; Touw DJ; Thomson AH
J Antimicrob Chemother; 2019 Aug; 74(8):2311-2317. PubMed ID: 31322695
[TBL] [Abstract][Full Text] [Related]
38. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.
Zelenitsky SA; Harding GK; Sun S; Ubhi K; Ariano RE
J Antimicrob Chemother; 2003 Oct; 52(4):668-74. PubMed ID: 12951354
[TBL] [Abstract][Full Text] [Related]
39. Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods.
Dopfer R; Brand P; Müllinger B; Hunger T; Häussermann S; Meyer T; Scheuch G; Siekmeier R
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 1):141-54. PubMed ID: 18204125
[TBL] [Abstract][Full Text] [Related]
40. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia.
Treerat P; Widmer F; Middleton PG; Iredell J; George AM
FEMS Microbiol Lett; 2008 Aug; 285(1):40-50. PubMed ID: 18513356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
